Hepatic and renal safety profile of tenofovir in HIV-infected patients with Hepatitis C, including patients on interferon plus ribavirin

HIV Clinical Trials

Volumn 6, Issue 5, 2005, Pages 278-280

  Sánchez Conde, Matilde ^a   Gil, Paloma ^a   Sánchez Somolinos, Mar ^a   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Hepatis C; HIV; Kidney; Liver; Ribavirin; Tenofovir; Toxicity

Indexed keywords

DIDANOSINE; EFAVIRENZ; LIVER ENZYME; REBETRON; TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; KIDNEY; LIVER; MALE; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 29744443777     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/FRWE-HCGF-K3BG-DG8P     Document Type: Article

References (21)

1. den Brinker M, Wit F, Wertheim-van Dillen P, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
2. Wit F, Weverling G, Weel J, Jurriaans S, Lange J. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
3. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003;32:259-267.
4. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36-43.
5. Martinez E, Blanco JL, Arnaiz J, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
6. Martín-Carbonero L, Núñez M, González-Lahoz JM, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115-120.
7. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
8. Barditch-Crovo P, Deeks S, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
9. Antoniou T, Park-Wyllie L, Tseng A. Tenofovir: a nucleotide analog for the management of HIV infection. Pharmacotherapy. 2003;23:29-43.
10. Gallant J, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944-950.
11. Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595-612.
12. Nuñez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis. 2003;37(12):1678-1685.
13. Klein M, Campeol N, Lalonde R, Brenner B, Wainberg M. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS. 2003;17:1001-1008.
14. Butt A. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read. 2003;13:344-348.
15. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004;9:133-138.
16. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960-963.
17. James C, Steinhaus M, Szabo S, Dressier R. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415-418.
18. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-273.
19. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-1333.
20. Margot N, Miller N. In vitro anti-HIV combination studies of ribavirin with tenofovir and other nucleoside analogs. In: Program and abstracts of the 2nd IAS Conference; 2003; Paris. Abstract 980.
21. Núñez M, Maida I, Berdún M, on behalf of the PRESCO Team. Efficacy and safety of pegylated interferon alpha-2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. In: Program and abstracts of the 44th ICAAC; 2004; Washington, DC. Abstract V-1148.